WEKO3
アイテム
{"_buckets": {"deposit": "e09efdcc-eb10-4836-ae9b-bceefc9ed6a3"}, "_deposit": {"created_by": 18, "id": "3225", "owners": [18], "pid": {"revision_id": 0, "type": "depid", "value": "3225"}, "status": "published"}, "_oai": {"id": "oai:air.repo.nii.ac.jp:00003225", "sets": ["1161"]}, "author_link": ["10214", "10221", "4773", "10212", "9476", "9471", "6135", "9470", "597", "10213", "10218", "9468", "6408", "9472", "9490", "9491"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3/4", "bibliographicPageEnd": "92", "bibliographicPageStart": "87", "bibliographicVolumeNumber": "44", "bibliographic_titles": [{"bibliographic_title": "秋田医学"}, {"bibliographic_title": "AKITA JOURNAL OF MEDICINE", "bibliographic_titleLang": "en"}]}]}, "item_10001_description_5": {"attribute_name": "内容記述(抄録)", "attribute_value_mlt": [{"subitem_description": "[Background and Aims] The combination therapy of transarterial chemoembolization (TACE) plus sorafenib has been applied for unresectable hepatocellular carcinoma (HCC). However, its efficacy remains controversial, possibly due to the timing of the initiation of sorafenib treatment. We evaluated the efficacy of this combination therapy when sorafenib treatment was initiated soon after the patient recovered from the adverse events due to the initial TACE procedure. \n[Methods] This was a retrospective study at a single hospital. Twenty-three unresectable HCC cases who exceeded the up-to-seven criteria but who showed no major vascular invasion or extrahepatic metastasis were enrolled in this study. The patients were classified into two groups : Group C (n=7) received combination therapy ; Group T (n=16) received TACE as the sole therapy. The time-to-tumor progression (TTP) and overall survival (OS) of the two groups were compared. [Results] The median TTP in Groups C and T was 1,737 days and 422 days, respectively (p \u003c 0.05). The median survival time (MST) after the initiation of each therapy in Groups C and T was 1,780 days and 371 days, respectively (p \u003c 0.05). [Conclusion] The TTP and OS of patients with unresectable HCC who received TACE plus sorafenib (administered soon after the initial TACE procedure) were superior to those in patients who received TACE alone.", "subitem_description_type": "Other"}]}, "item_10001_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.20569/00003585", "subitem_identifier_reg_type": "JaLC"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "秋田医学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00009294", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03866106", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "SUGIMOTO, Yuko"}], "nameIdentifiers": [{"nameIdentifier": "10213", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SATO, Wataru"}], "nameIdentifiers": [{"nameIdentifier": "9471", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SUZUKI, Toshiaki"}], "nameIdentifiers": [{"nameIdentifier": "4773", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MATSUZAWA, Hisanori"}], "nameIdentifiers": [{"nameIdentifier": "10218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MINAMI, Shinichiro"}], "nameIdentifiers": [{"nameIdentifier": "9476", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TAKAHASHI, Kenichi"}], "nameIdentifiers": [{"nameIdentifier": "10214", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "ARATA, Suguru"}], "nameIdentifiers": [{"nameIdentifier": "10212", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SHIBUYA, Tomomi"}], "nameIdentifiers": [{"nameIdentifier": "9470", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "CHIBA, Mitsuru"}], "nameIdentifiers": [{"nameIdentifier": "597", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "DOHMEN, Takahiro"}], "nameIdentifiers": [{"nameIdentifier": "9472", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHSHIMA, Shigetoshi"}], "nameIdentifiers": [{"nameIdentifier": "9468", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TOZAWA, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "9491", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "ISHIYAMA, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "9490", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashimoto, Manabu"}], "nameIdentifiers": [{"nameIdentifier": "6408", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "GOTO, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "6135", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "IIJIMA, Katsunori"}], "nameIdentifiers": [{"nameIdentifier": "10221", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-07-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "akitai44_3_4(87).pdf", "filesize": [{"value": "617.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 617900.0, "url": {"label": "akitai44_3_4(87)", "url": "https://air.repo.nii.ac.jp/record/3225/files/akitai44_3_4(87).pdf"}, "version_id": "fd3479b5-7587-43d4-8d75-74189fd855de"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "TACE", "subitem_subject_scheme": "Other"}, {"subitem_subject": "sorafenib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "combination therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "unresectable HCC", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A COMPARISON OF THE THERAPEUTIC EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION AND COMBINATION THERAPY WITH TRANSARTERIAL CHEMOEMBOLIZATION PLUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A COMPARISON OF THE THERAPEUTIC EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION AND COMBINATION THERAPY WITH TRANSARTERIAL CHEMOEMBOLIZATION PLUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA"}]}, "item_type_id": "10001", "owner": "18", "path": ["1161"], "permalink_uri": "https://doi.org/10.20569/00003585", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-07-05"}, "publish_date": "2018-07-05", "publish_status": "0", "recid": "3225", "relation": {}, "relation_version_is_last": true, "title": ["A COMPARISON OF THE THERAPEUTIC EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION AND COMBINATION THERAPY WITH TRANSARTERIAL CHEMOEMBOLIZATION PLUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA"], "weko_shared_id": -1}
A COMPARISON OF THE THERAPEUTIC EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION AND COMBINATION THERAPY WITH TRANSARTERIAL CHEMOEMBOLIZATION PLUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
https://doi.org/10.20569/00003585
https://doi.org/10.20569/0000358554983968-5951-440b-ae10-5fdce8cb0362
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-07-05 | |||||
タイトル | ||||||
タイトル | A COMPARISON OF THE THERAPEUTIC EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION AND COMBINATION THERAPY WITH TRANSARTERIAL CHEMOEMBOLIZATION PLUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | TACE | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | sorafenib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | combination therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | unresectable HCC | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
ID登録 | ||||||
ID登録 | 10.20569/00003585 | |||||
ID登録タイプ | JaLC | |||||
著者 |
SUGIMOTO, Yuko
× SUGIMOTO, Yuko× SATO, Wataru× SUZUKI, Toshiaki× MATSUZAWA, Hisanori× MINAMI, Shinichiro× TAKAHASHI, Kenichi× ARATA, Suguru× SHIBUYA, Tomomi× CHIBA, Mitsuru× DOHMEN, Takahiro× OHSHIMA, Shigetoshi× TOZAWA, Tomoki× ISHIYAMA, Koichi× Hashimoto, Manabu× GOTO, Takashi× IIJIMA, Katsunori |
|||||
内容記述(抄録) | ||||||
内容記述タイプ | Other | |||||
内容記述 | [Background and Aims] The combination therapy of transarterial chemoembolization (TACE) plus sorafenib has been applied for unresectable hepatocellular carcinoma (HCC). However, its efficacy remains controversial, possibly due to the timing of the initiation of sorafenib treatment. We evaluated the efficacy of this combination therapy when sorafenib treatment was initiated soon after the patient recovered from the adverse events due to the initial TACE procedure. [Methods] This was a retrospective study at a single hospital. Twenty-three unresectable HCC cases who exceeded the up-to-seven criteria but who showed no major vascular invasion or extrahepatic metastasis were enrolled in this study. The patients were classified into two groups : Group C (n=7) received combination therapy ; Group T (n=16) received TACE as the sole therapy. The time-to-tumor progression (TTP) and overall survival (OS) of the two groups were compared. [Results] The median TTP in Groups C and T was 1,737 days and 422 days, respectively (p < 0.05). The median survival time (MST) after the initiation of each therapy in Groups C and T was 1,780 days and 371 days, respectively (p < 0.05). [Conclusion] The TTP and OS of patients with unresectable HCC who received TACE plus sorafenib (administered soon after the initial TACE procedure) were superior to those in patients who received TACE alone. |
|||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
書誌情報 |
秋田医学 en : AKITA JOURNAL OF MEDICINE 巻 44, 号 3/4, p. 87-92, 発行日 2018-03 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03866106 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00009294 | |||||
出版者 | ||||||
出版者 | 秋田医学会 |